Patents by Inventor Alan W. Hruza

Alan W. Hruza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor XIa inhibitors
    Patent number: 9944643
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Alan W. Hruza, Zahid Hussain, Charles Lesburg, Remond Moningka
  • Factor XIa inhibitors
    Patent number: 9676723
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 13, 2017
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Zhuyan Guo, Alan W. Hruza, Zahid Hussain, Remond Moningka, Nancy Jo Kevin
  • Factor XIa inhibitors
    Patent number: 9663527
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: May 30, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Zhuyan Guo, Alan W. Hruza, Zahid Hussain, Charles A. Lesburg, Remond Moningka, Anthony K. Ogawa, Rudrajit Mal
  • FACTOR XIa INHIBITORS
    Publication number: 20160376272
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: February 6, 2015
    Publication date: December 29, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Alan W. Hruza, Zahid Hussain, Charles Lesburg, Remond Moningka
  • FACTOR XIa INHIBITORS
    Publication number: 20160347757
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: February 6, 2015
    Publication date: December 1, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Zhuyan Guo, Alan W. Hruza, Zahid Hussain, Charles A. Lesburg, Remond Moningka, Anthony K. Ogawa, Rudrajit Mal
  • FACTOR XIa INHIBITORS
    Publication number: 20160340315
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: February 6, 2015
    Publication date: November 24, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Zhuyan Guo, Alan W. Hruza, Zahid Hussain, Remond Moningka, Nancy Jo Kevin
  • Factor IXa crystals, related complexes and methods
    Patent number: 8710188
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: April 29, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brian M. Beyer, Alan W. Hruza, Richard N. Ingram, Vincent S. Madison, Andrew J. Prongay, Paul Reichert
  • Crystal of human interferon alpha 2B in complex with zinc
    Patent number: 8679472
    Abstract: This application covers a novel PEGylated interferon and a novel crystalline form of interferon which are useful, inter alia, for detailed structural analysis of interferon as well as treatment and prevention of viral infections and hyperproliferative diseases such as leukemia.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: March 25, 2014
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Paul Reichert, Marianna Marshall Long, Alan W. Hruza, Peter Orth, Tattanahalli L. Nagabhushan
  • Compounds that are ERK inhibitors
    Patent number: 8546404
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: October 1, 2013
    Assignee: Merck Sharp & Dohme
    Inventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, Jr., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
  • Factor IXa Crystals, Related Complexes and Methods
    Publication number: 20130157281
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Application
    Filed: May 31, 2011
    Publication date: June 20, 2013
    Applicant: SCHERING CORPORATION
    Inventors: BRIAN M. BEYER, ALAN W. HRUZA, RICHARD N. INGRAM, VINCENT S. MADISON, ANDREW J. PRONGAY, PAUL REICHERT
  • Factor IXa crystals, related complexes and methods
    Patent number: 7968683
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: June 28, 2011
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Alan W. Hruza, Richard N. Ingram, Vincent S. Madison, Andrew J. Prongay, Paul Reichert
  • Novel compounds that are ERK inhibitors
    Publication number: 20090118284
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: June 5, 2007
    Publication date: May 7, 2009
    Inventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, JR., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
  • High affinity quinoline-based kinase ligands
    Patent number: 7511063
    Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: March 31, 2009
    Assignee: Schering Corporation
    Inventors: Yongqi Deng, Patrick J. Curran, Gerald W. Shipps, Jr., Lianyun Zhao, M. Arshad Siddiqui, Janeta Popovici-Muller, Jose S. Duca, Alan W. Hruza, Thierry O. Fischmann, Vincent S. Madison, Rumin Zhang, Charles W. McNemar, Todd W. Mayhood, William T. Windsor, Emma M. Lees, David A. Parry
  • Novel high affinity quinoline-based kinase ligands
    Publication number: 20080045568
    Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
    Type: Application
    Filed: August 16, 2006
    Publication date: February 21, 2008
    Inventors: Yongqi Deng, Patrick J. Curran, Gerald W. Shipps, Lianyun Zhao, M. Arshad Siddiqui, Janeta Popovici-Muller, Jose S. Duca, Alan W. Hruza, Thierry O. Fischmann, Vincent S. Madison, Rumin Zhang, Charles W. McNemar, Todd W. Mayhood, William T. Windsor, Emma M. Lees, David A. Parry
  • Crystalline protein controlled release compositions
    Patent number: 6004549
    Abstract: A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: December 21, 1999
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Alan W. Hruza, Nagamani Nagabushan, Tattanahalli Nagabhushan